skip to primary navigationskip to content
 

Antibacterial agents in clinical development - An analysis of the antibacterial clinical development pipeline, including tuberculosis (World Health Organization, 2017)

This report shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.

The report – “Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including Mycobacterium tuberculosis” – shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance. Most of the drugs currently in the clinical pipeline are modifications of existing classes of antibiotics and are only short-term solutions. The report found very few potential treatment options for those antibiotic-resistant infections identified by WHO as posing the greatest threat to health, including drug-resistant tuberculosis which kills around 250 000 people each year. In addition to multidrug-resistant tuberculosis, WHO has identified 12 classes of priority pathogens – some of them causing common infections such as pneumonia or urinary tract infections – that are increasingly resistant to existing antibiotics and urgently in need of new treatments.

 

Please read the report here.

The Global Challenges Initiative is a Strategic Research Initiative of the University of Cambridge that aims to enhance the contribution of its research towards addressing global challenges and achieving the Sustainable Development Goals (SDGs) by 2030.

SDGs

Find out about open funding opportunities, pre-call announcements, responsive calls, studentships and awards relevant to the global challenges agenda.

Read more